Press release
ESR1-Mutated Metastatic Breast Cancer Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies - Roche, Sermonix Pharmaceutical, Sanofi
DelveInsight's "ESR1-Mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the ESR1-Mutated Metastatic Breast Cancer, historical and forecasted epidemiology as well as the ESR1-Mutated Metastatic Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The ESR1-Mutated Metastatic Breast Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the ESR1-Mutated Metastatic Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; ESR1-Mutated Metastatic Breast Cancer Market Insights https://www.delveinsight.com/report-store/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
ESR1-Mutated Metastatic Breast Cancer Overview
Breast cancer occurs when cells in the breast grow out of control and form a growth or tumor. Tumors may be cancerous (malignant) or not cancerous (benign). A small percentage of all breast cancers cluster in families. These cancers are described as hereditary and are associated with inherited gene mutations.
Mutations in the estrogen receptor gene (ESR1) are acquired frequently in metastatic hormone receptor-positive breast cancer. ESR1 mutations are acquired most frequently when aromatase inhibitors are used to treat advanced breast cancer.
Some of the key facts of the ESR1-Mutated Metastatic Breast Cancer Market Report:
• The ESR1-Mutated Metastatic Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Mutations affecting the ESR1 gene have been detected mainly in metastases from ER-positive/HER2-negative breast tumors, at a frequency ranging from 5 to 25%
• According to the World Health Organization, breast cancer results in more than one million new cases worldwide.
• Key ESR1-Mutated Metastatic Breast Cancer Companies: Roche, Sermonix Pharmaceutical, Sanofi, and others
• Key ESR1-Mutated Metastatic Breast Cancer Therapies: Giredestrant, Lasofoxifene, SAR439859, and others
Get a Free sample for the ESR1-Mutated Metastatic Breast Cancer Market Report https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Key benefits of the ESR1-Mutated Metastatic Breast Cancer Market report:
1. ESR1-Mutated Metastatic Breast Cancer market report covers a descriptive overview and comprehensive insight of the ESR1-Mutated Metastatic Breast Cancer Epidemiology and ESR1-Mutated Metastatic Breast Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The ESR1-Mutated Metastatic Breast Cancer market report provides insights on the current and emerging therapies.
3. ESR1-Mutated Metastatic Breast Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The ESR1-Mutated Metastatic Breast Cancer market report offers an edge that will help develop business strategies by understanding trends shaping and driving the ESR1-Mutated Metastatic Breast Cancer market.
Download the report to understand which factors are driving ESR1-Mutated Metastatic Breast Cancer epidemiology trends @ ESR1-Mutated Metastatic Breast Cancer Epidemiological Insights https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
ESR1-Mutated Metastatic Breast Cancer Market
The dynamics of the ESR1-Mutated Metastatic Breast Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
ESR1-Mutated Metastatic Breast Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
ESR1-Mutated Metastatic Breast Cancer Epidemiology Segmentation:
The ESR1-Mutated Metastatic Breast Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of ESR1-Mutated Metastatic Breast Cancer
• Prevalent Cases of ESR1-Mutated Metastatic Breast Cancer by severity
• Gender-specific Prevalence of ESR1-Mutated Metastatic Breast Cancer
• Diagnosed Cases of Episodic and Chronic ESR1-Mutated Metastatic Breast Cancer
ESR1-Mutated Metastatic Breast Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the ESR1-Mutated Metastatic Breast Cancer market or expected to get launched during the study period. The analysis covers ESR1-Mutated Metastatic Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the ESR1-Mutated Metastatic Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major ESR1-Mutated Metastatic Breast Cancer market share @ ESR1-Mutated Metastatic Breast Cancer market forecast
https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
ESR1-Mutated Metastatic Breast Cancer Therapies and Key Companies
• Giredestrant: Roche
• Lasofoxifene: Sermonix Pharmaceutical
• SAR439859: Sanofi
ESR1-Mutated Metastatic Breast Cancer Market Drivers
• Increased incidence of ESR1-mutations in breast cancer in the 7MM
• Increasing demand of novel drugs for ESR1 mutation treatment
Scope of the ESR1-Mutated Metastatic Breast Cancer Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key ESR1-Mutated Metastatic Breast Cancer Companies: Roche, Sermonix Pharmaceutical, Sanofi, and others
• Key ESR1-Mutated Metastatic Breast Cancer Therapies: Giredestrant, Lasofoxifene, SAR439859, and others
• ESR1-Mutated Metastatic Breast Cancer Therapeutic Assessment: ESR1-Mutated Metastatic Breast Cancer current marketed and ESR1-Mutated Metastatic Breast Cancer emerging therapies
• ESR1-Mutated Metastatic Breast Cancer Market Dynamics: ESR1-Mutated Metastatic Breast Cancer market drivers and ESR1-Mutated Metastatic Breast Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• ESR1-Mutated Metastatic Breast Cancer Unmet Needs, KOL's views, Analyst's views, ESR1-Mutated Metastatic Breast Cancer Market Access and Reimbursement
ESR1-Mutated Metastatic Breast Cancer Market Barriers
• Challenges in the identification of ESR1 mutations in standard clinical practice
• There is a paucity of ER-positive PDX models from MBC patients, especially patients with ESR1 mutations
Table of Contents
1. ESR1-Mutated Metastatic Breast Cancer Market Report Introduction
2. Executive Summary for ESR1-Mutated Metastatic Breast Cancer
3. SWOT analysis of ESR1-Mutated Metastatic Breast Cancer
4. ESR1-Mutated Metastatic Breast Cancer Patient Share (%) Overview at a Glance
5. ESR1-Mutated Metastatic Breast Cancer Market Overview at a Glance
6. ESR1-Mutated Metastatic Breast Cancer Disease Background and Overview
7. ESR1-Mutated Metastatic Breast Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of ESR1-Mutated Metastatic Breast Cancer
9. ESR1-Mutated Metastatic Breast Cancer Current Treatment and Medical Practices
10. ESR1-Mutated Metastatic Breast Cancer Unmet Needs
11. ESR1-Mutated Metastatic Breast Cancer Emerging Therapies
12. ESR1-Mutated Metastatic Breast Cancer Market Outlook
13. Country-Wise ESR1-Mutated Metastatic Breast Cancer Market Analysis (2019-2032)
14. ESR1-Mutated Metastatic Breast Cancer Market Access and Reimbursement of Therapies
15. ESR1-Mutated Metastatic Breast Cancer Market Drivers
16. ESR1-Mutated Metastatic Breast Cancer Market Barriers
17. ESR1-Mutated Metastatic Breast Cancer Appendix
18. ESR1-Mutated Metastatic Breast Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about ESR1-Mutated Metastatic Breast Cancer treatment, visit @ ESR1-Mutated Metastatic Breast Cancer Medications
https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
ESR1-Mutated Metastatic Breast Cancer Pipeline https://www.delveinsight.com/report-store/esr1-mutated-metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"ESR1-Mutated Metastatic Breast Cancer Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the ESR1-Mutated Metastatic Breast Cancer market. A detailed picture of the ESR1-Mutated Metastatic Breast Cancer pipeline landscape is provided, which includes the disease overview and ESR1-Mutated Metastatic Breast Cancer treatment guidelines.
ESR1-Mutated Metastatic Breast Cancer Epidemiology https://www.delveinsight.com/report-store/esr1-mutated-metastatic-breast-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'ESR1-Mutated Metastatic Breast Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted ESR1-Mutated Metastatic Breast Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ESR1-Mutated Metastatic Breast Cancer Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies - Roche, Sermonix Pharmaceutical, Sanofi here
News-ID: 2850723 • Views: …
More Releases from DelveInsight Business Research
Global Uterine Fibroids Treatment Devices Market is projected by DelveInsight to …
DelveInsight's latest publication, "Uterine Fibroids Treatment Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive evaluation of the current market status, future opportunities, upcoming technological advancements, key challenges, and major growth determinants. The report also highlights breakthrough products under development and profiles the prominent companies actively shaping the Uterine Fibroids Treatment Devices industry.
According to DelveInsight's analysis, the growing prevalence of uterine fibroids particularly among women of reproductive age…
Global AI in Remote Patient Monitoring Market Forecasted to Grow at 27.13% CAGR …
According to DelveInsight's analysis, North America is expected to dominate the Artificial Intelligence (AI) in Remote Patient Monitoring market from 2025 through 2032. This strong regional performance is attributed to the growing burden of chronic illnesses including cancer well-established healthcare infrastructure, rapid adoption of digital health technologies, and supportive government policies. Additionally, increased investment in digital health and the widespread use of wearables and connected medical devices are significantly accelerating…
DelveInsight Strengthens Pharma Decision-Making with Advanced Competitive Intell …
As the pharmaceutical industry accelerates toward rapid innovation and heightened competition, access to timely, actionable intelligence has become indispensable. DelveInsight, a premier life sciences market research and consulting organization, has launched an enhanced Competitive Intelligence (CI) News Monitoring service designed to equip pharmaceutical companies with real-time insights into clinical, regulatory, and commercial developments. This solution is reshaping how organizations interpret market shifts and make evidence-based strategic decisions.
Stay Ahead of the…
DelveInsight Releases In-Depth Market & Competitive Intelligence Report on the G …
DelveInsight, a prominent provider of life sciences market research and strategic consulting, has announced the publication of its latest analytical report, "Market & Competitive Assessment: Mapping Commercial Success in the Cell Imaging Technology Domain." This comprehensive study delivers a rigorous, data-driven evaluation of the worldwide market for cell imaging and analysis systems, with a dedicated focus on software-enabled platforms such as High-Content Screening (HCS) instruments, flow cytometers, and cell analyzers.…
More Releases for ESR1
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Set for Steady Growth A …
The global market for ESR1 mutated metastatic breast cancer diagnostics is projected to grow from USD 64.61 million in 2025 to USD 92.92 million by 2035, reflecting a compound annual growth rate (CAGR) of 3.7%, according to the latest market analysis. This growth trajectory is driven by the rising prevalence of ESR1 mutations in metastatic breast cancer patients, increasing demand for early and precise diagnostic solutions, and ongoing innovations in…
ESR1 mutated metastatic breast cancer Market Analysis 2034 - Competitive Landsca …
The ESR1-mutated metastatic breast cancer companies are AstraZeneca, Olema Pharmaceuticals, Arvinas, Sermonix Pharmaceuticals, Roche, Eli Lilly and Company, H3 Biomedicine, Eisai, Pfizer, Sun Pharma Advanced Research Company, Zenopharm, Daiichi Sankyo, and others.
ESR1-mutated metastatic breast cancer market, valued at approximately USD 1.3 billion in 2023, is projected to experience substantial growth during the forecast period (2024-2034). Furthermore, the US accounts for the largest market share, representing approximately 63% of the total…
United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market valuation …
"The global ESR1 mutated metastatic breast cancer diagnostics market size reached US$ 63.51 Million in 2024 from US$ 61.05 Million in 2023 and is expected to reach US$ 93.21 Million by 2033, growing at a CAGR of 4.4% during the forecast period 2025-2033." As per DataM intelligence research report
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/esr1-mutated-metastatic-breast-cancer-diagnostics-market?sp
United States: Recent Industry Developments
✅ In September 2025, Guardant Health launched…
FDA Approves INLURIYO (Imlunestrant): A Game-Changer for ESR1-Mutated Metastatic …
The pharmaceutical landscape for metastatic breast cancer treatment has witnessed a significant milestone with the FDA approval of INLURIYO (imlunestrant) on September 25, 2025. Eli Lilly's innovative, world-first oral selective estrogen receptor degrader (SERD) represents the first endocrine therapy innovation specifically targeting ESR1 mutations in over two decades, addressing a critical unmet medical need in estrogen receptor-positive (ER+), HER2-negative breast cancer patients.
Image: https://www.abnewswire.com/upload/2025/09/ccb2e17e2f3a2721c027dabdf0f1bd92.jpg
The pharmaceutical landscape for metastatic breast cancer treatment…
ESR1-Mutated Metastatic Breast Cancer Market Set for Significant Growth by 2034, …
DelveInsight's "ESR1 Mutated Metastatic Breast Cancer - Market Insight, Epidemiology And Market Forecast - 2034" [https://www.delveinsight.com/report-store/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr] report delivers comprehensive insights into the disease landscape, historical and forecasted epidemiology, as well as ESR1 Mutated Metastatic Breast Cancer market trends across the 7MM (United States, EU4 [Germany, France, Italy, and Spain], United Kingdom, and Japan). The report reveals that the ESR1-mutated metastatic breast cancer market, valued at approximately USD 1.3 billion in…
ESR1-Mutated Metastatic Breast Cancer Market Industry Analysis by Size, Share, G …
Introduction
The ESR1-Mutated Metastatic Breast Cancer Market focuses on a specific subtype of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer characterized by mutations in the estrogen receptor 1 (ESR1) gene. These mutations confer resistance to standard endocrine therapies such as aromatase inhibitors, making the disease more difficult to manage and highlighting the need for novel targeted approaches.
In recent years, the emergence of oral selective estrogen receptor degraders (SERDs), next-generation endocrine therapies,…
